

Universitätsklinikum Carl Gustav Carus

DIE DRESDNER.

SAHOCCELL®

UCARE



Lunch Talk

30th Jan 2023 1 pm

House 66, 3rd floor

**CD19 CAR T B cell
depletion with KYV-
101 for autoimmune
diseases**

Dominic Borie

Kyverna Therapeutics*

You are welcome to join us for a **meet
and greet** with lunch **starting 12 pm.**

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna's pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.